Nathalie Franchimont

Prior to joining Nimbus, Nathalie served as Senior Vice President, Head of Multiple Sclerosis (MS) and Immunology Development Unit at Biogen. She has also previously held a variety of other leadership roles at Biogen, including leading the Multiple Sclerosis Research and Early Development Unit, the New Indications Research and Early Development Unit and the Immunology Drug Innovation Unit. Prior to joining Biogen, Nathalie held Medical Affairs and Clinical Research roles at Amgen. Nathalie also has served on the Board of OMASS Therapeutics since 2020.

Nathalie completed her Rheumatology training at the University of Liège and has held research fellow roles at the University of Connecticut School of Medicine, Yale University School of Medicine, and University of Liège.